| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014128591 |
| Title |
Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors of Janus- Related Kinases (Jak). |
| Abstract |
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them. |
| Applicant(s) |
Pfizer Inc |
| Representative Drug(s) |
D0KL3B |
Drug Info
|
IC50 = 1300 nM |
Click to Show More |
[1] |
|
2
|
D0FQ4Z
|
Drug Info
|
IC50 > 10000 nM
|
[1] |
| Patent ID |
WO2013092854 |
| Title |
Pyrimidine-2,4-Diamine Derivatives As Kinase Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I) wherein X, R, Y0, T0A, T0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compositions including said compoundsand their use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Representative Drug(s) |
D0LR6J |
Drug Info
|
IC50 = 100 to 1000 nM |
Click to Show More |
[2] |
|
2
|
D0S6XT
|
Drug Info
|
IC50 = 100 to 1000 nM
|
[2] |
|
3
|
D0SJ1Q
|
Drug Info
|
IC50 < 100 nM
|
[2] |
| Patent ID |
WO2015173683 |
| Title |
Pyrazolopyridines and Pyrazolopyrimidines. |
| Abstract |
A compound having the structure: A compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A' are independently C or N, where C may be unsubstituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), and -(CH2)n-W, where W is C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N, S and/or 0 atoms, -SO2-R', -NHSO2-R', -NR"SO2-R' and SR', where R' and R" are independently C1-C6 alkyl or C3-C8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C1-C6 alkyl, C1-C6 alkoxy, etc., or (b) -(CH2)n-W, where W is C3-C8cycloalkyl, phenyl, etc.; R1 is H, halo or cyano; R2 and R2' are independently H, C1-C6 alkyl, cyano, C1-C6 alkoxy, C1-C6 alkylthio, or C3-C8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, -CO-, -CONH-, -S02-, -SONH-, or -(CH2)m-; R3 is H, C1-C4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent -Y-R4 and/or 1 -4 substituents each independently selected from R5; with the proviso that when X is -CO- or -SO2-, R3 is not H; Y is a bond, -(CH2)m- or -O-; R4 is (a) H, C1-C6 alkyl, C3-C8 cycloalkl, halo, oxo, -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1 -5 substituents selected from C1-C6 alkyl, C3-C8 cycloalkyl, halo, cyano, -OR6, -NR7R8, etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R6 is H, C1-C6 alkyl or C3-C8 cycloalkyl, etc.; R7 and R8 are each independently H, C1-C6 alkyl or C3-C8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1 -2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C1-C6 alkyl is optionally substituted by C3-C8 cycloalkyl, ha lo, etc., and said heterocyclic ring being optionally substituted by one or more C1-C6 alkyl or C3-C8 cycloalkyli groups; R9 is C1-C6 alkyl or C3-C8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD. |
| Applicant(s) |
Pfizer Inc |
| Representative Drug(s) |
D03QAY |
Drug Info
|
IC50 = 4.7 nM |
[1] |
| Patent ID |
WO2015164614 |
| Title |
Janus Kinase Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides kinase inhibitors, such as compounds of Formula (I) and Formula (II). The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and/or treating and/or preventing a condition associated with aberrant activity of a kinase (e.g., a proliferative disease, inflammatory disorder, autoimmune disorder, painful condition, and/or viral infection). (I) (II). |
| Applicant(s) |
DANA-FARBER CANCER INSTITUTE, INC. |
| Representative Drug(s) |
D01DBB |
Drug Info
|
IC50 = 2000 nM |
[2] |
| Patent ID |
WO2015164604 |
| Title |
Hydrophobically Tagged Janus Kinase Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides Janus kinase inhibitors, such as compounds of Formula (I) and Formula (II) wherein RY1 and RY2 comprise a tagged hydrophobic moiety RH. The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). The hydrophobic moiety RH may signal to the intracellular protein homeostasis machinery to induce degradation of the targeted kinase. Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and/or treating and/or preventing a condition associated with aberrant activity of a kinase (e.g., a proliferative disease, inflammatory disorder, autoimmune disorder, painful condition, and/or viral infection). |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Patent ID |
WO2015148867 |
| Title |
Substituted Heteroaryl Compounds and Methods of Use. |
| Abstract |
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease. |
| Applicant(s) |
Calitor Sciences, Llc |
| Representative Drug(s) |
D0GB7G |
Drug Info
|
IC50 = 7 nM |
[2] |
| Patent ID |
WO2015144773 |
| Title |
New Compounds. |
| Abstract |
The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals. |
| Applicant(s) |
Novartis Tiergesundheit Ag |
| Patent ID |
WO2015131080 |
| Title |
Tyk2 Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. |
| Applicant(s) |
Nimbus Lakshmi, Inc |
| Representative Drug(s) |
D0NY6M |
Drug Info
|
Ki < 10 nM |
[1] |
| Patent ID |
WO2015123453 |
| Title |
Pyridazine Compounds As Jak Inhibitors. |
| Abstract |
In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a condition or disorder mediated at least in part by JAK kinase activity are also described. |
| Applicant(s) |
Portola Pharmaceuticals, Inc |
| Patent ID |
WO2015110378 |
| Title |
Benzimidazole Derivatives and Pharmaceutical Compositions Thereof for The Treatment of Inflammatory Disorders. |
| Abstract |
The present invention discloses compounds according to Formula (I) wherein Cy, R1, L1 R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula (I), able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons. |
| Applicant(s) |
Galapagos Nv |
| Representative Drug(s) |
D01CRX |
Drug Info
|
IC50 = 0.1 to 50 nM |
[2] |
| Patent ID |
WO2015091584 |
| Title |
Thiazolopyridine Compounds, Compositions and Their Use As Tyk2 Kinase Inhibitors. |
| Abstract |
Provided are thiazolopyridine compounds that are inhibitors of TYK2 kinase, compositions containing these compounds and methods for treating diseases mediated by TYK2 kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where X, R0, R1, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by TYK2 kinase in a patient. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Patent ID |
WO2015032423 |
| Title |
Pharmaceutical Compounds. |
| Abstract |
The invention provides a compound which is an amide of the formula (2): or a salt or stereoisomer thereof; wherein: R7 is selected from chlorine and fluorine; R3, R4, R5 and R6 are each independently selected from hydrogen, fluorine and chlorine; n is 0, 1 or 2; Q1 is selected from C(=O), S(=O) and SO2; A is absent or is NR2; R1 is selected from: - hydrogen; - an optionally substituted C1-6 non-aromatic hydrocarbon group; and - 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted; R2 is selected from hydrogen and C1-4 alkyl; or NR1R2 forms an optionally substituted 4- to 7-membered non-aromatic nitrogen- containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen; with the provisos that: (i) no more than two of R3 to R6 are other than hydrogen; and (ii) when R7 and R6 are both fluorine, then one of R3 to R5 is chlorine or fluorine and/or R1-A-Q1 is selected from ethylsulfonyl and isopropylsulfonyl. Also provided are pharmaceutical compositions containing the compounds and their therapeutic uses. |
| Applicant(s) |
Sareum Limited |
| Representative Drug(s) |
D05AXE |
Drug Info
|
IC50 = 0.6 nM |
[1] |
| Patent ID |
WO2014123167 |
| Title |
Tricyclic Pyrrolopyridine Compound, and Jak Inhibitor. |
| Abstract |
The present invention addresses the problem of providing a novel tricyclic pyrrolopyridine compound which has a JAK inhibitory activity, and is particularly useful for preventing, treating and/or alleviating autoimmune diseases, inflammatory diseases, or allergic diseases. Provided is a novel tricyclic pyrrolopyridine compound represented by formula (I) (the substituents in the formula are defined in detail in the description, however R1 represents a C1-6 alkyl group, or the like, R2 represents a hydrogen atom, or the like, R3 represents a hydrogen atom, or the like, ring A represents a C3-11 cycloalkane, or the like, L1 represents a C1-6 alkylene group, or the like, and R4 represents NRaRb, or the like), a tautomer of said compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt. |
| Applicant(s) |
Nissan Chemical Industries, Ltd |
| Representative Drug(s) |
D04BOW |
Drug Info
|
IC50 = 19 nM |
[1] |
| Patent ID |
WO2014019908 |
| Title |
Substituted Pyrroles Active As Kinases Inhibitors. |
| Abstract |
The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them. |
| Applicant(s) |
Nerviano Medical Sciences S.R.L |
| Patent ID |
WO2014000032 |
| Title |
Phenyl Amino Pyrimidine Bicyclic Compounds and Uses Thereof. |
| Abstract |
The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. |
| Applicant(s) |
Ym Biosciences Australia Pty Ltd |
| Representative Drug(s) |
D0RJ3W |
Drug Info
|
IC50 = 0.69 nM |
[1] |
| Patent ID |
WO2013189771 |
| Title |
Aminotriazolopyridine for Use In The Treatment of Inflammation, and Pharmaceutical Compositions Thereof. |
| Abstract |
The present invention relates to the novel medical use of the compound according to Formula I, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound. |
| Applicant(s) |
Galapagos Nv |
| Representative Drug(s) |
D09ALF |
Drug Info
|
IC50 > 3000 nM |
[2] |
| Patent ID |
WO2013174895 |
| Title |
Heterocyclyl Pyrimidine Analogues As Tyk2 Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I), wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Representative Drug(s) |
D0M2OK |
Drug Info
|
IC50 < 10 nM |
[2] |
| Patent ID |
WO2013117649 |
| Title |
Imidazo [4, 5 -C] Pyridine Derivatives Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Patent ID |
WO2013117646 |
| Title |
Novel Compound Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
A novel imidazolopyridine according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Patent ID |
WO2013117645 |
| Title |
Imidazo [4, 5 -C] Pyridine Derivatives Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Representative Drug(s) |
D07PTU |
Drug Info
|
IC50 = 0.01 to 100 nM |
[2] |
| Patent ID |
WO2013055645 |
| Title |
5,7-Substituted-Imidazo[1,2-C]Pyrimidines. |
| Abstract |
Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities. |
| Applicant(s) |
Array Biopharma Inc |
| Representative Drug(s) |
D0U1HA |
Drug Info
|
IC50 < 10 nM |
[2] |
| Patent ID |
WO2013041605 |
| Title |
Pyrazolo[4,3-C]Pyridine Derivatives As Kinase Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I) wherein X1 to X5, Y, ZA, ZB, R and A have the meaning as cited in the description and the claims. Said compounds are useful as kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically- mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as the use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Representative Drug(s) |
D09PIS |
Drug Info
|
IC50 > 10000 nM |
[2] |
| Patent ID |
WO2013041539 |
| Title |
Imidazopyridine Compounds, Compositions and Methods of Use. |
| Abstract |
The invention provides TYK2 inhibitors of Formulas (la-lb), stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, Ra, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas (la-lb) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in the therapy of inflammatory diseases. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0IB3R |
Drug Info
|
IC50 = 0.4 nM |
[1] |
| Patent ID |
WO2013024895 |
| Title |
Tricyclic Heterocyclic Compounds and Jak Inhibitors. |
| Abstract |
Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a, L2a, L3a and na are as defined in the description. |
| Applicant(s) |
Nissan Chemical Industries, Ltd |
| Patent ID |
WO2013014162 |
| Title |
Heterocyclyl Pyrimidine Analogues As Jak Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I), wherein X1 to X5, Z1 to Z3, Y0, RY1, RY2 and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically- mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Representative Drug(s) |
D01FVC |
Drug Info
|
IC50 = 1000 to 10000 nM |
[2] |
| Patent ID |
WO2013007768 |
| Title |
Tricyclic Heterocyclic Compounds, Compositions and Methods of Use Thereof As Jak Inhibitors. |
| Abstract |
The invention provides novel compounds of formula I having the general formula:(I) wherein Rl s R2, R3, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0M2WA |
Drug Info
|
IC50 = 3 nM |
[1] |
| Patent ID |
WO2013007765 |
| Title |
Fused Tricyclic Compounds for Use As Inhibitors of Janus Kinases. |
| Abstract |
The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0LS1O |
Drug Info
|
IC50 = 38 nM |
[1] |
| Patent ID |
WO2015016206 |
| Title |
Heterocyclic Compound. |
| Abstract |
The present invention provides a prophylactic or therapeutic agent for autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus) and the like, the agent having excellent Tyk2 inhibitory effect. The present invention pertains to a compound or salt thereof represented by formula (I) (in the formula, the reference signs are as defined in the present specification). |
| Applicant(s) |
Takeda Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0M2JK |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014157569 |
| Title |
Heterocyclic Compound. |
| Abstract |
Provided is a compound having an excellent JAK-inhibiting effect, the compound being is useful as an agent for the prevention or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, infl. |
| Applicant(s) |
Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D01GNL |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013180265 |
| Title |
Heterocyclic Compound. |
| Abstract |
Provided is a compound having an excellent JAK inhibitory activity and therefore useful as a prophylactic or therapeutic agent for autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, inflammat. |
| Applicant(s) |
Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0T6CY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013146963 |
| Title |
Heterocyclic Compound. |
| Abstract |
Provided is an agent for preventing or treating autoimmune disorders and the like (for example, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, and the like) that has excellent Tyk2 inhibiting activity. The present invention pertains to a compound expressed by the formula (1) (where the symbols are as defined in the specification), or to a salt thereof. |
| Applicant(s) |
Takeda Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0M8YW |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013125543 |
| Title |
Heterocyclic Compound. |
| Abstract |
Provided is a prophylactic or therapeutic agent for autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, sy. |
| Applicant(s) |
Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0C3HN |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011075334 |
| Title |
Pyrrolo[2,3-D]Pyrimidine Compounds. |
| Abstract |
Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation. (Formula (I)). |
| Applicant(s) |
Pfizer Inc |
